The GALAD score was developed in 2015 and incorporates Gender, Age, and three biomarkers: AFP, AFP-L3%, and DCP to improve the detection of HCC, specifically in patients with chronic liver disease. This evidence concerns the gene AFP and hepatocellular carcinoma.